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https://doi.org/10.1016/j.stemcr.2018.08.004SUMMARYHematopoietic stem cells (HSCs) develop in the embryonic aorta-gonad-mesonephros (AGM) region and subsequently relocate to fetal
liver. Runx1 transcription factor is essential for HSC development, but is largely dispensable for adult HSCs. Here, we studied tamoxifen-
inducible Runx1 inactivation in vivo. Induction at pre-liver stages (up to embryonic day 10.5) reduced erythromyeloid progenitor
numbers, but surprisingly did not block the appearance of Runx1-null HSCs in liver. By contrast, ex vivo analysis showed an absolute
Runx1 dependency of HSC development in the AGM region. We found that, contrary to current beliefs, significant Cre-inducing tamox-
ifen activity persists in mouse blood for at least 72 hr after injection. This deferred recombination can hit healthy HSCs, which escaped
early Runx1 ablation and result in appearance of Runx1-null HSCs in liver. Such extended recombination activity in vivo is a potential
source of misinterpretation, particularly in analysis of dynamic developmental processes during embryogenesis.INTRODUCTION
In the mouse, the first transient hematopoietic waves
(primitive erythroid and erythromyeloid progenitors
[EMPs]) emerge extra-embryonically in the early yolk
(McGrath et al., 2015; Palis et al., 1999). HSCs, which
give rise to the adult hematopoietic system, appear only
by mid-gestation intra-embryonically within the aorta-
gonad-mesonephros (AGM) region (Ciau-Uitz et al., 2016;
Medvinsky and Dzierzak, 1996; Medvinsky et al., 1993;
Muller et al., 1994). HSCs emerge predominantly from
the endothelial floor of the dorsal aorta (de Bruijn et al.,
2002; North et al., 2002; Taoudi and Medvinsky, 2007)
through amaturation process defined by inductive interac-
tions within the AGM region (Fitch et al., 2012; Souilhol
et al., 2016a) and signals from somites (Clements et al.,
2011; Lee et al., 2014; Pouget et al., 2014). The origin of
HSCs from aortic endothelium is supported by strong
evidence in non-mammalian vertebrates and in humans
(Bertrand et al., 2010; Ivanovs et al., 2014; Kissa andHerbo-
mel, 2010).
Various signaling pathways are involved in early hemato-
poietic development (reviewed in [Ciau-Uitz et al., 2016]).
HSCmaturation in the mouse is a multistep process driven
by SCF and IL3 (Robin et al., 2006; Rybtsov et al., 2011,
2014), accompanied by temporal changing signaling re-
quirements for Notch, Shh, and Bmp (Gama-Norton et al.,
2015; Lizama et al., 2015; Peeters et al., 2009; Richard
et al., 2013; Souilhol et al., 2016a, 2016b). It is reasonable
to assume that exact transcription factor machinery also784 Stem Cell Reports j Vol. 11 j 784–794 j September 11, 2018 j ª 2018
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for Runx1, a transcription factor essential for HSC develop-
ment, but which is far less significant in adult bonemarrow
HSCs (Cai et al., 2011; North et al., 1999; Okuda et al.,
1996; Putz et al., 2006). EMPs and HSCs originate from
different endothelial subsets through a Runx1-dependent
process (Chen et al., 2011; Eliades et al., 2016; Lie et al.,
2018). Conditional Runx1 ablation in vivo blocks the endo-
thelial to EMP/HSC transition prior to liver colonization
(Chen et al., 2009). More detailed analysis using a robust
AGM explant system recapitulating HSC development,
showed that, up to embryonic day 11.5 (E11.5) (immedi-
ately prior to fetal liver colonization), HSC development
absolutely depends on Runx1, but EMPs become Runx1 in-
dependent at earlier stages (Tober et al., 2013).
Here we followed the consequences of induced Runx1
ablation in the AGM region on HSC development in the
fetal liver. We used a tamoxifen (4-OHT)-inducible Cre-
ERT2 system to delete Runx1 and assessed the presence of
EMPs and definitive HSCs in the E13.5 fetal liver. We
observed a significant reduction of EMP numbers, but, con-
trary to our expectations and in apparent discrepancy with
a previous report (Tober et al., 2013), we detected signifi-
cant numbers of Runx1-null HSCs in the liver, implying
that HSC development in the AGM region does not require
Runx1. We then performed in vivo injections of 4-OHT, but
in this case isolated E11.5 AGM regions and after culture
transplanted them into irradiated recipients. We found
no Runx1-null HSCs in repopulated irradiated recipients,
which is in conflict with results of in vivo analysis.ecommons.org/licenses/by-nc-nd/4.0/).
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In search of an explanation, we tested how long 4-OHT
or/and its active derivatives (cumulatively termed here
4-OHT/Der) remain in the circulation of adult mouse and
found that, at least 3 days after injection, concentration
of 4-OHT/Der in the peripheral blood of the animal re-
mains sufficient to cause significant (up to 20%) Cre-medi-
ated recombination in cells. Therefore, those HSCs, which
have not recombined during the AGM stage could proceed
with development, but could be hit by recombination later
when Runx1 is no longer essential. This would inevitably
lead to emergence of functionally active Runx1-null HSCs
in the fetal liver. Such a problem does not exist when the
AGM region is removed from the mouse and explanted in
fresh culture medium free of 4-OHT/Der.
Thus, despite the advantages of in vivo analysis in princi-
ple, poor control over in utero development may bring
about a significant uncertainty and cause misinterpreta-
tion of results. By contrast, the functionally validated and
robustly controlled ex vivo system provides strong evidence
for the essential role of Runx1 in HSC development, in
keeping with previously published results.RESULTS
4-OHT-Induced Runx1 Ablation at E8.5–E9.5, but Not
Thereafter, Reduces EMP Formation
Here, we studied effects of in-vivo-induced stage-specific
Runx1 ablation on the appearance of EMPs in fetal liver.
To this end, pregnant [Rosa26CreERT2:sGFP:Runx1fl/fl] fe-
males crossed with [Rosa26CreERT2::sGFP::Runx1wt/fl] males
were treated with a single dose of 4-OHT between 8.5 and
10.5 days of gestation at a concentration of 2 mg/mouse.
E13.5 litters containing both homozygous Runx1fl/fl and
heterozygous Runx1wt/fl (control) embryos were harvested,
and cell suspensions prepared from individual livers were
analyzed in methylcellulose colony-forming unit (CFU)
assays (Figure 1A). In homozygous Runx1fl/fl embryos
([Rosa26CreERT2::sGFP::Runx1fl/fl]), 4-OHT injections at
E8.5 or E9.5 led to a significant reduction of fetal liver
EMPs by 50% compared with Runx1wt/fl heterozygous
[Rosa26CreERT2::sGFP::Runx1wt/fl] controls (Figure 1B, blueFigure 1. Tamoxifen (4-OHT)-Induced Runx1 Ablation at E8.5–E9
(A) Experimental design: studying the effect of conditional Runx
intraperitoneally (i.p.) to [Rosa26CreERT2::sGFP::Runx1fl/fl] pregnant
E8.5–E10.5. E13.5 embryos were collected and EMPs from individual FL
4-OHT-induced E13.5 GFP+ embryo is shown.
(B) Left: numbers of E13.5 FL EMPs per embryo equivalent (e.e.). Tim
standard errors are shown (three independent experiments, at least thr
were performed (**p = 0.001; ***p = 0.0002). Right: Runx1 recombi
progenitors after 4-OHT injection at pre-liver stages, indicating the pe
mean values and standard errors shown).
(C) Representative Runx1 genotyping PCR gels of EMP colonies, show
786 Stem Cell Reports j Vol. 11 j 784–794 j September 11, 2018and red bars). However, 4-OHT injection at later stage
(E10.5) had no effect on EMPs in fetal livers (Figure 1B,
green bars), indicating the essential role of Runx1 in EMP
development at early stages but not after E10.5. This result
is in agreement with temporal Runx1 dependency in em-
bryonic EMPs reported previously (Tober et al., 2013).
To confirm this conclusion, we tested the status of Runx1
loci in individual fetal liver EMPs using PCR. We picked
only liver-derived methylcellulose colonies expressing
GFP, indicative of prior activity of Cre-recombinase. Due
to their clonal origin, PCR analysis of individual CFU col-
onies reveals the Runx1 status of individual EMPs. We
found that a fraction of tested colonies (20%–36%) escaped
any Runx1 recombination despite activation of GFP (Fig-
ures 1B right, 1C, and S1A; Table 1). The recombined frac-
tion (64%–80%) contained those colonies that retained
one intact Runx1 allele (Runx1fl/D) or had both loci recom-
bined (Runx1D/D). Of note, 4-OHT injection at E8.5, E9.5,
and E10.5 resulted in progressive growth of the proportion
of Runx1D/D EMPs in the FL (11%, 25%, and 47%, respec-
tively) (Figures 1B right and 1C; Table 1). A particularly
high fraction of Runx1D/D EMPs was observed after 4-OHT
injection at E10.5, when no reduction of EMP numbers
was observed. All together this implies progressive acquisi-
tion of Runx1 independency by EMPs during development,
in line with a previous report (Tober et al., 2013).Induced Runx1 Ablation from E9.5 onward Does Not
Eliminate HSC Development in the Fetal Liver
We tested whether a single 4-OHT injection between E8.5
and E10.5 would block HSC development in vivo. After in-
jection, embryos continued development in utero until
E13.5. Cells from individual E13.5 fetal livers were then
isolated and transplanted separately into irradiated recipi-
ents, as depicted in (Figure 2A). To our surprise, robust
multilineage donor-derived long-term engraftment was
observed in all 37 recipient animals, regardless of injection
time (Figure 2B, left, and data not shown). Cre activity in
these experiments was very efficient as seen by the pres-
ence of a large GFP+ cell fraction in most recipients
(ranging from 85% to 97%, Figure S2)..5, but Not Thereafter, Reduces EMP Formation
1 deletion on EMPs. A single dose of 4-OHT was administered
females crossed with [Rosa26CreERT2::sGFP::Runx1wt/fl] males at
s quantified by clonogenic methylcellulose assays. A representative
e of i.p. injection indicated for, e.g., as ipE8.5. Mean values and
ee embryos in each experiment). Unpaired Student t statistical tests
nation in [Rosa26CreERT2::sGFP::Runx1fl/fl] E13.5 FL erythromyeloid
rcentage of each genotype (at least two independent experiments;
ing wt, fl, and D bands.
Table 1. Runx1 Status of E13.5 Fetal Liver GFP+ Erythromyeloid Progenitors (CFU-Cs) Derived from Individual Embryos after 4-OHT
Injection at Pre-liver Stages
Experiment Embryo Genotype
Embryos with Runx1 Recombined Alleles/Total Embryos (Recombination Range)
Total
Colonies
Analyzed
CFU-Cs in E13.5 FL
wt/D fl/D D/D
iE8.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 9/9 (11%–42%) 111
R26CreERT2::Runx1fl/fl 12/13 (17–86%) 9/13 (6%–33%) 159
iE9.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 7/7 (8%–58%) 85
R26CreERT2::Runx1fl/fl 13/13 (14%–80%) 11/13 (8%–67%) 134
iE10.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 5/6 (33%–100%) 36
R26CreERT2::Runx1fl/fl 10/12 (20%–80%) 11/12 (20%–100%) 60
Recombination range refers to proportion of recombined colonies.Since Cre-mediated GFP activation does not guarantee
Runx1 recombination in the same cells, the recombination
status of Runx1was verified using PCR. To this end, individ-
ual donor-derived GFP+ colonies obtained from blood and
bone marrow of long-term (16 weeks) reconstituted ani-
mals were analyzed by PCR (Figures 2B right, 2C, and
S1B; Table 2). When 4-OHT was injected at E8.5, all but
one GFP+ donor-derived methylcellulose colonies ob-
tained cumulatively from 18 recipients contained at least
one functional Runx1 allele, indicating that Runx1D/D
HSCs did not develop. However, injection at E9.5 gave a
significant proportion of donor-derived Runx1D/D colonies
(17%) in 13 repopulated recipients. Injection at E10.5 re-
sulted in further increase (33%) of Runx1D/D donor-derived
colonies obtained from long-term transplanted animals (a
total of six recipients were analyzed) (Figures 2B right and
2C; Table 2).
Taken alone, these results suggest that Runx1 is not
required for HSC development from as early as E9.5, which
contradicts the previous report showing Runx1 depen-
dency of HSC development up to E11.5 (Tober et al.,
2013). We investigated reasons for this discrepancy as
described below.
Active Concentrations of 4-OHTor/and Its Derivatives
Persist in the Mouse for No Less than 72 hr
We reasoned that if, after 4-OHT injection, recombination
does not occur in all cells at once and 4-OHT activity
continues further, HSCs (known to become Runx1 inde-
pendent when fully mature) may undergo late Runx1 abla-
tion without adverse consequences. Upon transplantation,
such Runx1-null HSCs could be generating Runx1D/D prog-
eny detectable in the methylcellulose assay.
To investigate this possibility, we tested how long
4-OHT/Der persists in the mouse and causes recombina-
tion. To this end, wild-type C57BL/6 adult females wereintraperitoneally injected with 4-OHT, and serum obtained
at different time points after injection was added to cul-
tures of primary AGM cells isolated from E10.5 and E11.5
[RosaCreERT2::sGFP] embryos (Gilchrist et al., 2003) (Fig-
ure 3A). We observed maximum recombination efficiency
(100% GFP activation) using serum obtained 5 hr after
4-OHT administration. Nevertheless, serum collected after
48 and 72 hr could also cause 20%–40% recombination
(Figure 3B). Specifically, 72 hr serum caused 52% ± 8.7%
recombination in CD45+ cells, 16% ± 7.6% in VE-Cad+
cells, and 26% ± 13.2% in stromal cells (CD45VE-Cad–)
(data not shown). (Note that recombination in non-
hematopoietic cells is underestimated due to knownmosa-
icism of GFP expression in non-hematopoietic cells in
these mice [Gilchrist et al., 2003]).
These experiments show that, after injection of 4-OHT,
cells in the mouse containing loxP sites can recombine
over a period of at least 3 days. Thus, those cells in the
embryo which have not undergone rapid Cre-mediated
recombination of the Runx1flox allele continue to be
exposed to 4-OHT/Der and can recombine, even 3 days af-
ter 4-OHT injection.
The extended circulation of 4-OHT/Der in vivo creates
uncertainty as to when exactly during development
Runx1 becomes dispensable for HSC development. The
next set of experiments was designed to control and reduce
the duration ofHSC exposure to 4-OHT/Der to obtainmore
interpretable results.
Runx1 Deletion at E9.5 Abrogates HSC Activity in the
E11.5 AGM Region
To avoid prolonged exposure to 4-OHT/Der, we switched
from the entirely in vivo design to experiments incorpo-
rating a highly controllable in vitroHSCmaturation system
(Rybtsov et al., 2011, 2014; Taoudi et al., 2008). As in previ-
ous setups, embryos for these experiments contained eitherStem Cell Reports j Vol. 11 j 784–794 j September 11, 2018 787
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Figure 2. Induced Runx1 Ablation from E9.5 onward Does not Eliminate HSC Development in the Fetal Liver
(A) Experimental design analogous to that described in Figure 1A, with cell suspensions from individual E13.5 FL embryos transplanted
into irradiated adult mice.
(B) Left: donor-derived contribution in recipient mice blood 16 weeks after transplantation is shown. Each point represents an individual
recipient mouse, representing data from at least two independent experiments. Numbers of analyzed mice for Runx1wt/fl+ 4-OH-T series
(legend continued on next page)
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Table 2. Runx1 Status of E13.5 Fetal Liver HSCs Assessed by PCR Analysis of Donor-Derived GFP+ Erythromyeloid Progenitors from
Long-Term Engrafted Recipients
Experiment Embryo Genotype
Embryos with Runx1 Recombined Alleles/Total Embryos (Recombination Range)
Total
Colonies
Analyzed
HSC-Derived CFU-Cs (BM + Blood)
wt/D fl/D D/D
iE8.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 3/7 (17%–50%) 33
R26CreERT2::Runx1fl/fl 8/11 (33%–100%) 1/11 (8%) 89
iE9.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 5/5 (6%–55%) 63
R26CreERT2::Runx1fl/fl 8/8 (18%–80%) 5/8 (10%–40%) 143
iE10.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 2/3 (71%–100%) 9
R26CreERT2::Runx1fl/fl 3/3 (31%–54%) 3/3 (23%–44%) 52
Recombination range refers to proportion of recombined colonies.both or one conditional Runx1 allele (Runx1fl/fl and
Runx1wt/fl, respectively). 4-OHT was administered in vivo
at E9.5 as described previously; but, instead of allowing
the embryos develop in utero until E13.5, E11.5 AGM re-
gions were dissected and individually explanted (Medvin-
sky and Dzierzak, 1996). Placement of the AGM region in
fresh culture medium ends the exposure of developing
HSCs to 4-OHT/Der. After 4 days in culture, AGM cells
were transplanted into irradiated recipients (Figure 4A).
Twelve recipients transplanted with control
[Rosa26CreERT2::sGFP::Runx1wt/fl] AGM cells showed
high-level, long-term multilineage donor-derived
engraftment. Fourteen of 16 recipients transplanted with
[Rosa26CreERT2:: sGFP::Runx1fl/fl] AGM cells were also repo-
pulated at high level (only one showed low-level
donor-derived chimerism and one lacked engraftment)
(Figure 4B). We observed highly efficient GFP recombina-
tion in [Rosa26CreERT2::sGFP::Runx1wt/fl] and [Rosa26
CreERT2::sGFP::Runx1fl/fl] repopulated cells (98% and
89%, respectively) (Figure S3). However, analysis of
methylcellulose colonies obtained from these 14 long-
term repopulated mice showed that, by contrast to liver,
[Rosa26CreERT2:: sGFP::Runx1fl/fl] AGM region transplants
contained no Runx1D/D HSCs (repopulated mice gave no
Runx1D/Dmyeloid colonies) (Figure 4C; Table 3), indicating
an absolute requirement of Runx1 for HSC development
prior to liver colonization. Of note, variance in efficiency
of recombination suggests a considerable difference in
accessibility of loxP sites for Cre-mediated recombination
between GFP and Runx1 loci.(ipE8.5, ipE9.5, and ipE10.5) were 6, 10, and 10, respectively; for Runx
respectively. Right: Runx1 status of [Rosa26CreERT2::sGFP::Runx1fl/fl] E
progenitors from long-term (16 weeks) engrafted recipients. Percenta
values and standard errors) are shown.
(C) Representative Runx1 genotyping PCR gels of HSC-derived progenDISCUSSION
During maturation, pre-HSCs undergo massive expansion
in the AGM region, sequentially upregulating hematopoi-
etic CD41, CD43, and CD45, and some other markers
(Boisset et al., 2015; Ferkowicz et al., 2003; Rybtsov
et al., 2011, 2014, 2016; Taoudi et al., 2008; Tober et al.,
2018; Zhou et al., 2016). This stepwise developmental
process is driven by dynamic gene actions. Temporal
requirements for genes driving HSC development can
vary, and accurate staging of gene involvement is essential
for understanding this process. For example, acquisition
of adult phenotype is accompanied by gradual loss of
Notch, Shh, and Bmp dependency by HSCs in the AGM
region (Gama-Norton et al., 2015; Lizama et al., 2015;
Peeters et al., 2009; Richard et al., 2013; Souilhol et al.,
2016a, 2016b).
Runx1 is a key transcription factor involved in EMP and
HSC development (Cai et al., 2000; Chen et al., 2009;
North et al., 2002; Okuda et al., 1996). However, exact ac-
tion points of Runx1 during this multistep process require
clarification. Initial hematopoietic specification associated
with upregulation of CD41 does not require Runx1 (Liakho-
vitskaia et al., 2014). Runx1 sensitivity of the embryonic
endothelium is limited to the period around E7.5–E8.5
(Tanaka et al., 2012; Yzaguirre et al., 2018). Induced
stage-specific inactivation using explant cultures followed
by long-term transplantations showed that, up to E11.5,
Runx1 is absolutely required for HSC development but be-
comes dispensable after that (Tober et al., 2013). Here we1fl/fl+ 4-OH-T series (ipE8.5, ipE9.5, and ipE10.5) were 18, 13, and 6,
13.5 FL HSCs, assessed by analysis of donor-derived erythromyeloid
ges of each genotype (at least two independent experiments; mean
itors, indicating wt, fl, and D bands, are shown.
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Figure 3. Active Concentrations of 4-OHT
or/and Its Derivatives Remain in the
Mouse for No Less than 72 hr
(A) Experimental schematics: wild-type
C57BL/6 adult females were intraperitone-
ally injected with 4-OHT and serum obtained
at different time points after injection.
Then, it was added to cultures of primary
E10.5 and E11.5 [RosaCreERT2::sGFP] AGM
cells, and recombination was assessed by
monitoring GFP expression by fluorescence-
activated cell sorting after 24 hr.
(B) GFP recombination in AGM cells upon
incubation with serum isolated at different
time points (0, 5, 20, 48, and 72 hr) after
4-OH-tamoxifen intraperitoneal injection
(at least two independent experiments;
three mice/experiment; mean values and
standard errors are shown).explored whether the conclusions of this study can be
corroborated by in vivo tracking.
To this end, we injected pregnant females with 4-OHT
during active EMP/HSC formation. Instead of analysis of
E11.5 AGM explants (Tober et al., 2013), we followed
HSC development in utero up to E13.5 in the fetal liver.
Injections at E8.5/E9.5, but not at E10.5, reduced EMP
numbers in the E13.5 liver, indicating that by this stage
EMPs become Runx1 independent, whichwas corroborated
by increased emergence of Runx1D/D, in agreement with
previously reported results (Tober et al., 2013).
We then focused on the HSC development. After a single
4-OHT injection at E8.5, E9.5, or E10.5, the embryos were
allowed to develop in utero up to E13.5, after which fetal
liver cells were transplanted into irradiated recipients.
Unexpectedly, all long-term repopulated animals (trans-
planted with E9.5 cells onward) contained Runx1-null790 Stem Cell Reports j Vol. 11 j 784–794 j September 11, 2018HSCs, in apparent contradiction with previous data ob-
tained in AGM cultures (Tober et al., 2013).
We then reasoned that in vivo results might depend on
the persistence of 4-OHT/Der activity in the mouse.
Indeed, 4-OHT injections at E8.5/E9.5 yielded non-recom-
bined (Runx1fl/fl) and partly recombined (Runx1fl/D) HSCs. If
4-OHT/Der persisted in the mouse beyond E11.5 stage
(when HSCs become Runx1 independent), delayed recom-
bination could transform non-recombined (Runx1fl/fl) and
partly recombined (Runx1fl/D) HSCs into Runx1D/D HSCs
without adverse effect. Indeed, we found that substantial
4-OHT/Der activity, capable of inducingCRE-ERT2, persists
in the mouse for at least 3 days, introducing major uncer-
tainty as to when exactly recombination took place and
making in vivo experiments poorly interpretable. Crucially,
under highly controlled experimental conditions, where
after a single 4-OHT injection at E9.5, E11.5 AGM regions
A B
C
Figure 4. Runx1 Deletion at E9.5 Abro-
gates HSCActivity in the E11.5AGMRegion
(A) 4-OHT-induced Runx1 deletion was per-
formed at E9.5 as described in Figure 1A, but
embryos were harvested at E11.5. AGM re-
gions were dissected and cultured as ex-
plants for 4 days, and cell suspensions from
individual explants were transplanted into
irradiated adult mice.
(B) Donor-derived engraftment in the blood
from recipient mice 16 weeks after trans-
plantation is shown. Each point represents
an individual recipient mouse (data from
three independent experiments). Numbers
of analyzed mice for Runx1wt/fl and
Runx1fl/fl+ 4-OH-T conditions were 12 and
16, respectively.
(C) Top: recipient mice were sacrificed
16weeks after transplantation and the Runx1
genotype was examined by PCR in individual
donor-derived GFP+ CFU-Cs from bone
marrow and blood. Runx1 genotype fre-
quencies within donor-engrafted mice are
plotted. Average and SE from embryos from
three independent experiments are given (no
production of Runx1D/D colonies observed).
Bottom: representative Runx1 genotyping
PCR gels of colonies, with Runx1 wt, fl, and
D bands shown.were isolated and cultured in fresh medium free of 4-OHT/
Der, subsequent transplantations showed complete abla-
tion of Runx1-null HSCs. This result points to a critical
role for Runx1 in HSC development in the AGM region
before colonization of the fetal liver, in agreement with a
previous report (Tober et al., 2013).
Interestingly, although we observed near 100% recombi-
nation of the GFP transgene, the efficiency of Runx1
recombination was significantly lower, emphasizing that
accessibility of loxP sites in various genetic loci further
confounds interpretation of in vivo results. Our recent
study exploring the role of Notch in HSC development
(Souilhol et al., 2016b) failed to obtain any useful data us-
ing in-utero-induced gene ablation due to the highly resis-
tant nature of the floxed RbpJk allele (our unpublished
data).
In summary, our current study shows a crucial role for
Runx1 in HSC development in the AGM region prior to
liver colonization, and emphasizes the value of in vitro
models recapitulating developmental processes. Although
studying biological processes in vivo is undeniably impor-
tant, experiments involving induced gene modifications
to analyze dynamic developmental processes in utero can
incur major uncertainties. We believe that recapitulation
of developmental processes in vitro using highly controlledconditions, supported by functional validation, will
continue to play an important role in various areas of devel-
opmental biology.EXPERIMENTAL PROCEDURES
Mice
All transgenic mice used to generate embryos and adult mice
were on the C57BL/6 (CD45.2/2) background. Rosa26CreERT2::
Runx1fl/fl and Rosa26CreERT2::sGFP::Runx1fl/fl mice were used to
obtain Rosa26CreERT2::sGFP::Runx1fl/fl conditional knockout and
Rosa26CreERT2::sGFP::Runx1wt/fl control embryos. The morning of
discovery of the vaginal plug was designated as day 0.5. E11.5 em-
bryos used had 41–45 somite pairs. C57BL/6 (CD45.1/CD45.2) an-
imals were used as recipients for transplantations. Rosa26CreERT2
were a gift from Lars Grotewold and Austin Smith, previously
used in (Souilhol et al., 2016b); Runx1fl/fl mice and silent GFP
(sGFP) mice were generated previously as described in (Putz et al.,
2006) and (Gilchrist et al., 2003), respectively. All experiments
with animals were performed under a Project License granted by
the Home Office (UK), University of Edinburgh Ethical Review
Committee, and conducted in accordance with local guidelines.
E11.5 AGM Explant Culture
AGM regions were dissected from E11.5 embryos and incubated
for 2 hr at 37C and 5% CO2 in IMDM medium (Invitrogen)Stem Cell Reports j Vol. 11 j 784–794 j September 11, 2018 791
Table 3. Runx1 Genotype of E11.5 AGM Explant HSCs Assessed by PCR Analysis of Donor-Derived GFP+ Erythromyeloid Progenitors
from Long-Term Engrafted Recipients
Experiment Embryo Genotype
Embryos with Runx1 Recombined Alleles/Total Embryos (Recombination Range)
Total
Colonies
Analyzed
HSC-Derived CFU-Cs (BM + Blood)
wt/D fl/D D/D
iE9.5 -> E13.5 FL R26CreERT2::Runx1wt/fl 4/6 (11%–43%) 71
R26CreERT2::Runx1fl/fl 10/12 (14%–64%) 0/12 (NA) 127
Recombination range refers to proportion of recombined colonies.
NA, not applicable.supplemented with 20% fetal calf serum (FCS) (HyClone, Fisher
Scientific), L-glutamine (L-Gln), and penicillin/streptomycin
(P/S). AGM regions were transferred individually onto 0.8 mm
mixed cellulose MF membranes (AAWP02500, Millipore) for
5–7 days (37C, 5% CO2) and cultured at the liquid-gas interface
with IMDM+ medium consisting of 20% FCS, L-Gln, P/S
IMDM, and growth factors (interleukin-3, SCF, and FLT3L,
100 ng/mL each; all from PeproTech). After 4 days of culture,
explants were dissociated by enzymatic digestion (collagenase/
dispase in PBS containing CaCl2 and MgCl2). Methylcellulose
CFU-C and long-term repopulation assays were subsequently
performed.
Hematopoietic Clonogenic Progenitor (CFU-C) and
Colony Genotyping
Cell suspensions from either fresh or cultured embryonic tissues
were plated into semi-solid Methocult M3434 medium (StemCell
Technologies). After 7–12 days of culture, CFU-C colonies were
scored and recombination in the Runx1 locus analyzed by PCR.
In brief, colonies were individually transferred into 50 mL of lysis
buffer, incubated for 1 hr at 56C followed by 5 min at 95C.
Runx1wt (251 bp), Runx1fl (325 bp), and Runx1D (382 bp)
products were amplified by simultaneously using the primers P5
(50-TAGGGAGTGCTGCTTGCTCT-30), P6 (50- GCCGGGTGCAA.
ATTAAGTC-30), and P7 (50-CTCTGGGAAACCAGGGAGTG-30), un-
der the following PCR conditions: 94C 5 min; [94C 30 s; 60C
30 s; 72C 1 min] 3 35 cycles; 72C 10 min.
Long-Term Hematopoietic Repopulation Assays
Cell suspensions from embryos at different stages were injected
into irradiated adult recipients (CD45.1/2) either directly (E13.5
FL, 0.2 embryo equivalents per recipient mouse) or after explant
culture (E11.5 AGM, 0.1 embryo equivalents per recipient mouse),
along with 80,000 CD45.1/1 bone marrow carrier cells. Recipients
were irradiated by split dose (472 + 472 rad with 3-hr interval) of g
irradiation. Donor-derived chimerismwasmonitored in blood at 6
and 16weeks after transplantation using FACScalibur (BD). Periph-
eral bloodwas collected by bleeding the lateral tail vein into 500 mL
5 mM EDTA/PBS, and erythrocytes were depleted using PharM
Lyse (BD). Cells were stained with anti-CD16/32 (Fc-block,
cat. no. 16-0161-86), CD45.1-APC (clone A20, cat. no. 17-0453-
82), and anti-CD45.2-PE (clone 104, cat. no. 12-0454-83) mono-
clonal antibodies (eBioscience). Appropriate isotype controls
were used. Dead cells were excluded using 7AAD (eBioscience).792 Stem Cell Reports j Vol. 11 j 784–794 j September 11, 2018Mice demonstratingR5% donor-derived multilineage chimerism
after 8 weeks were considered to be reconstituted.
Intraperitoneal Injections
Rosa26CreERT2::sGFP::Runx1fl/fl and Rosa26CreERT2::sGFP::Runx1wt/fl
embryos were induced in vivo by intraperitoneal injection of 2 mg
4-OHT (Sigma) into Rosa26CreERT2::sGFP::Runx1wt/fl x Rosa26
CreERT2::sGFP::Runx1fl/fl pregnant females. 4-OHT was prepared in
100% ethanol, diluted 1:10 in corn oil. Embryos were allowed to
develop in utero up to E11.5 or E13.5 before harvesting tissues for
analysis by CFU-C, flow cytometry, and repopulation assays.
Testing Persistence of 4-OHT in Peripheral Blood of
Adult Mice
C57BL/6 females were injected with 4-OHT as described above.
Peripheral blood was collected by submandibular bleeding before
4-OHT injection (0 hr), 5, 20, 48, and 72 hr following injection.
After centrifugation (4003 g/5min), serumwas collected and addi-
tionally centrifuged (400 3 g/5 min) to remove remaining blood
cells. Serum was frozen at 80C and used at the same time in
two independent sets of experiments. Total E10-11 AGM cells
cultured for 24 hr in IMDM + 50% mouse serum were collected
and analyzed by flow cytometry for GFP expression (dead cells
were excluded by 7AAD). In some cases the cells were stained
for CD45-PE (Pharmingen, cat. no. 553081) and VE-Cadherin-
AlexaFluor-647 (eBioscience, cat. no. 51-1441-82; 138006).
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